Analysts Set Larimar Therapeutics Price Target at $16.50

The biotech firm's stock receives strong buy ratings from research firms.

Apr. 9, 2026 at 11:53am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of metal gears, levers, and machinery in muted tones, conceptually representing the intricate financial infrastructure supporting a biotechnology company's operations.Detailed financial mechanics power the growth of a promising biotech firm's rare disease pipeline.Bala Cynwyd Today

Larimar Therapeutics, Inc. (NASDAQ:LRMR) has been assigned an average price target of $16.50 by the 10 research firms covering the company, according to MarketBeat Ratings. One analyst has a sell rating, six have buy ratings, and three have strong buy ratings on the stock.

Why it matters

Larimar Therapeutics is a clinical-stage biotech company focused on developing treatments for rare diseases using its novel cell-penetrating peptide technology. The strong analyst sentiment and price target suggest optimism about the company's pipeline and future growth potential.

The details

The average 12-month price target of $16.50 represents significant upside from Larimar's current trading price. Analysts at firms like Wedbush, Citigroup, and Truist Financial have all raised their price targets and ratings on the stock in recent months, citing progress with the company's lead drug candidate CTI-1601 for the treatment of Friedreich's ataxia.

  • Larimar Therapeutics reported Q1 2026 earnings on March 19, 2026.
  • Director James E. Flynn purchased 5 million shares of Larimar stock on February 27, 2026.

The players

Larimar Therapeutics, Inc.

A clinical-stage biotechnology company developing treatments for rare diseases using its novel cell-penetrating peptide technology platform.

James E. Flynn

A director at Larimar Therapeutics who purchased 5 million shares of the company's stock in February 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The strong analyst sentiment and price target for Larimar Therapeutics suggest the market sees significant potential in the company's rare disease pipeline and technology platform, despite the stock's recent volatility.